A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

Gastrointestinal Stromal Tumors Clinical Trial

Official title:

A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy, and Pharmacokinetics in Patients With Advanced Malignancies

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02571036
• Other study ID #: DCC-2618-01-001
• Status: Completed
• Phase: Phase 1
• Start date: November 2015
• Est. completion date: April 29, 2022

Study information

• Verified date: December 2023
• Source: Deciphera Pharmaceuticals LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of DCC-2618, administered orally (PO), in adult patients with advanced malignancies. The study consists of 2 parts, a dose-escalation phase, and an expansion phase. All active patients (from both dose-escalation and expansion phases) will then transition into an extension phase.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 282
• Est. completion date: April 29, 2022
• Est. primary completion date: April 29, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria (Escalation and Expansion Phases)

Patients must meet the following criteria to be eligible to enroll in the study:

1. Male or female patients =18 years of age.

2. Patients must have histologically confirmed solid tumors or hematologic malignancies.

Eligible patients include the following:

1. GIST patients must have a KIT and PDGFRA mutation and must have progressed on or had an intolerability to at least 1 line of systemic anticancer therapy.

2. SM patients must have a confirmed diagnosis of advanced SM according to 2016 World Health Organization (WHO) criteria for SM and must have documented KIT mutant disease. Patients with imatinib-sensitive KIT mutations must have progressed on or were intolerant to a tyrosine kinase inhibitor. Patients with advanced SM must present with at least 1 eligible C-Finding (organ damage) per 2013 International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis consensus response criteria; please see below for MCL exception. Advanced SM includes: i. Aggressive SM (ASM) ii. SM with associated hematologic neoplasm (SM-AHN), wherein the AHN does not require immediate alternative therapy. AHNs that are eligible include: low grade myelodysplastic syndrome (MDS) with a high SM burden who require treatment for SM only, myeloproliferative neoplasms (MPN), MDS/MPN, unclassifiable MDS, and HES/CEL. iii. MCL

• Patients with histopathologically-confirmed MCL without a C-finding are eligible. iv. Symptomatic SSM
• By definition, SSM patients must have at least 2 B-findings, and clinically significant symptom burden (eg, flushing, diarrhea, etc.) despite maximal treatment with approved agents to treat mediator symptoms, such as antihistamines and cromolyn sodium. v. Patients with hematologic malignancies featuring clonal expansion of eosinophils driven by genomic alterations of KIT or PDGFRA (eg, HES or CEL) are eligible if they have progressed on or are intolerant of imatinib therapy. Patients with de novo imatinib resistant mutations, such as but not limited to KIT D816V or PDGFRA D842V, are eligible without prior imatinib therapy. c. Malignant glioma patients with genomic alterations potentially conferring sensitivity to DCC-2618 including, but not limited to, amplification and/or mutations of PDGFRA and/or KIT. Other solid tumor patients that have alterations in genes encoding kinases that are

targets of DCC-2618. This includes:

• Melanoma
• Soft tissue sarcoma patients (including but not limited to: malignant peripheral nerve sheath tumors (MPNST), desmoplastic small round cell tumors (DSRCT), and dermatofibrosarcoma protuberans tumors (DFSP)
• Other solid tumor patients (non-melanoma, non-STS; specifically germ-cell, penile, and non-small cell lung carcinoma)
• Renal impairment cohort

3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of =2.

4. Adequate organ function and bone marrow function. Exclusion Criteria (Escalation and Expansion Phases)

Patients meeting any of the following criteria will be excluded from the study:

1. GIST patients with wild type or unknown KIT or PDGFRA status.

2. Patients with SM or other hematologic malignancies will be excluded if the following

apply:

1. SM patients with neutropenia accompanied by fever or infection, or thrombocytopenia associated with clinically significant bleeding.

• Patients with an infection that is well controlled with antibiotics are eligible if there is an immediate need for treatment.

2. SM-AHN patients diagnosed with:

i. SM with MDS who require treatment for MDS. ii. Patients requiring immediate treatment for AHN. c. Patients with leukemias, with the exception of MCL and CEL, that have progressed after imatinib. d. Eosinophilic myeloproliferative neoplasm patients: i. Lacking a mutation that is a known target of DCC-2618.

3. Prior or concurrent malignancy whose natural history or treatment have the potential to interfere with the safety or efficacy assessment of DCC-2618. Patients receiving adjuvant cancer treatment are not eligible if those medications are potentially active against GIST or excluded per protocol.

4. New York Heart Association class III and IV heart disease, active ischemia or any other uncontrolled cardiac condition such as angina pectoris, clinically significant cardiac arrhythmia requiring therapy, uncontrolled hypertension or congestive heart failure.

5. Arterial thrombotic or embolic events such as cerebrovascular accident (including ischemic attacks) or hemoptysis within 6 months before start of study drug.

6. Venous thrombotic events (eg, deep vein thrombosis) or pulmonary arterial events (eg, pulmonary embolism) within the 3 months before start of study drug. Patients with venous thrombotic events =3 months before start of study drug on stable anticoagulation therapy are eligible.

7. Baseline prolongation of the rate-corrected QT interval based on repeated demonstration of QT interval corrected by Fridericia's formula (QTcF) >450 ms in males or >470 ms in females or history of long QT interval corrected (QTc) syndrome.

8. Left ventricular ejection fraction (LVEF) <50% or below the lower limit of normal (whichever is higher).

9. Major surgery within 4 weeks of the first dose of study drug; following major surgeries >4 weeks prior to the first dose of study drug, all surgical wounds must be healed and free of infection or dehiscence.

10. Any other clinically significant comorbidities.

11. Illnesses that could affect oral absorption.

12. Known human immunodeficiency virus or active hepatitis C infection only if the patient is taking per protocol prohibited medications, active hepatitis B, or active hepatitis C infection.

13. If female, the patient is pregnant or lactating.

14. Known allergy or hypersensitivity to any component of the investigational drug product. Patients with history of Stevens-Johnson syndrome on a prior tyrosine kinase inhibitor (TKI) are excluded.

Related Conditions & MeSH terms

• Advanced Cancers
• Advanced Systemic Mastocytosis
• Gastrointestinal Stromal Tumors
• Mastocytosis

Intervention

Drug:
• DCC-2618
50 mg formulated tablets
• DCC-2618
10 mg and 50 mg formulated tablets

Locations

Country	Name	City	State
Canada	Princess Margaret Cancer Centre (GIST, other solid tumors)	Toronto
Germany	Uniklinik RWTH Aachen (mastocytosis, GIST, and other solid tumors)	Aachen
Germany	HELIOS Klinikum Berlin-Buch (GIST, and other solid tumors)	Berlin
Germany	Essen University Hospital (mastocytosis, GIST, and other solid tumors)	Essen
Germany	Freiburg University Hospital (mastocytosis, and other solid tumors)	Freiburg
Germany	University Medical Centre Mannheim (mastocytosis)	Mannheim
Italy	University Hospital of Verona (mastocytosis)	Verona
Netherlands	Leiden University Medical Center (GIST and other solid tumors)	Leiden
United Kingdom	Guy's Hospital (mastocytosis only)	London
United Kingdom	Royal Marsden Hospital (GIST, glial malignancies, other solid tumors)	London
United States	Dana Farber Cancer Institute (GIST, mastocytosis, glial malignancies, other solid tumors)	Boston	Massachusetts
United States	MD Anderson Cancer Center (GIST, mastocytosis, glial malignancies, other solid tumors)	Houston	Texas
United States	Mayo Clinic (GIST, mastocytosis, glial malignancies, other solid tumors)	Jacksonville	Florida
United States	UCLA (glial malignancies only)	Los Angeles	California
United States	UCLA Hematology Center (mastocytosis)	Los Angeles	California
United States	University of Miami (GIST, mastocytosis, glial malignancies, other solid tumors)	Miami	Florida
United States	Colombia University Medical Center (mastocytosis)	New York	New York
United States	Memorial Sloan Kettering Cancer Center (GIST, mastocytosis, glial malignancies, other solid tumors)	New York	New York
United States	Stanford University Comprehensive Cancer Center (GIST)	Palo Alto	California
United States	Stanford University Hematology Clinic (mastocytosis)	Palo Alto	California
United States	Fox Chase Cancer Center (GIST only)	Philadelphia	Pennsylvania
United States	OHSU (GIST & mastocytosis only)	Portland	Oregon
United States	Virginia Commonwealth University School of Medicine (mastocytosis)	Richmond	Virginia
United States	Huntsman Cancer Institute (GIST, mastocytosis, glial malignancies, other solid tumors)	Salt Lake City	Utah
United States	UCSF (glial malignancies only)	San Francisco	California
United States	Honor Health (GIST, mastocytosis, other solid tumors)	Scottsdale	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Deciphera Pharmaceuticals LLC

Countries where clinical trial is conducted

United States,  Canada,  Germany,  Italy,  Netherlands,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety/tolerability of oral DCC-2618: incidence of adverse events	Dose limiting toxicities, AEs, SAEs, discontinuation of drug due to toxicity, physical exams and ECOG PS, ophthalmologic examinations, changes from baseline in laboratory parameters, electrocardiograms, LVEF, and vital signs.	Approximately 24 months
Primary	Determination of the Maximum Tolerated Dose and the Recommended Phase 2 Dose		18 months
Primary	Expansion Phase: Assess Antitumor Activity of DCC-2618 in all diseases	Objective response rate (ORR); Disease control rate (DCR)	Approximately 24 months
Secondary	Determine the PK profile of oral DCC-2618		Predose and up to 24 hours postdose (Cycle = 28 Days)
Secondary	Escalation Phase: Assess Antitumor Activity of DCC-2618 in patients with advanced malignancies	Objective response rate (ORR); Disease control rate (DCR)	Approximately 24 months